Versant Capital Management’s TG Therapeutics TGTX Stock Holding History

Versant Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.2K	Hold	1,041	–	–	0.01%	1266
2026 Q1	$34.6K	Buy	1,041 +308	+42%	+$9.18K	﹤0.01%	1467
2025 Q4	$21.9K	Buy	733 +715	+3,972%	+$23.4K	﹤0.01%	1580
2025 Q3	$650	Hold	18	–	–	﹤0.01%	2548
2025 Q2	$648	Buy	+18	New	+$670	﹤0.01%	2533
2023 Q3	–	Sell	-26	Closed	-$646	–	2055
2023 Q2	$646	Buy	+26	New	+$672	﹤0.01%	1751

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Versant Capital Management's TGTX Position: Q2 2026 in Review

Versant Capital Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 1,041 shares worth $57.2K. The position accounts for 0.01% of the portfolio, ranked #1266.

Versant Capital Management first reported a position in TGTX in Q2 2023 and has held it in 6 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Versant Capital Management held 1,041 shares of TG Therapeutics worth $57.2K as of Q2 2026.
Versant Capital Management left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up 0.01% of Versant Capital Management's portfolio in Q2 2026, its #1266 holding.
Versant Capital Management first reported a position in TG Therapeutics in Q2 2023 and has held it in 6 quarters since.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.